BioCryst Pharmaceuticals (BCRX) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.81 -7.37%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OFLX, AFIB, NMRD, More
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OFLX, AFIB, NMRD, More
Join SI Premium – FREE
BioCryst Pharmaceuticals (Nasdaq: BCRX) reported Q1 loss of ($0.29), $0.09 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $17.04 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
